Endovascular Treatment of Patients with Critical Limb Ischemia - GIKEI

GRN Klinik Weinheim0 个研究点目标入组 50 人2018年11月12日

概览

暂无简介。

注册库

who.int

开始日期

2018年11月12日

结束日期

2018年10月1日

最后更新

去年

研究类型

Observational

性别

All

发起方

•1\. Fontaine Stages I or IIa without indication for endovascular treatment.
•2\. Acute limb\-threatening ischemia of iliac and femoral arteries with indication for treatment with heparin, low\-molecular heparins, new anticoagulants or cumadin.
•3\. Candidates requiring surgical revascularization or hybrid procedures after failed endovascular treatment
•4\. Severe renal failure, creatinine clearance \<30 mL/min
•5\. Platelet count \<100x109/L
•6\. Anemia with Hb\<10\.0 g/dL
•7\. History of or condition associated with increased bleeding risk including: trauma within 30 days before the index procedure, clinically significant gastrointestinal bleeding within the last 6 months, history of apoplexy within the last 3 months, fibrinolytics within 10 days before the index procedure, intracranial, intraocular, spinal, or atraumatic intra\-articular bleeding, chronic hemorrhagic disorder, known intracranial neoplasm, arteriovenous malformation, or aneurysm, sustained uncontrolled hypertension: systolic blood pressure \=180 mmHg or diastolic blood pressure \=100 mmHg, known significant liver disease (e.g., acute clinical hepatitis, liver cirrhosis)
•8\. Alcohol or drug abuse within 12 months before the index procedure.
•9\. Pregnancy, breast feeding or childbearing potential without proper contraceptive measures.
•10\. Indication for anticoagulation or dual platelet treatment due to atrial fibrillation, aortic valve replacement, vein thrombosis, acute coronary syndrome etc.